Related Experiment Video
Updated: Apr 11, 2026
10:06
Cellular Affinity of Particle-Stabilized Emulsion to Boost Antigen Internalization
Published on: September 2, 2022
2.4K
Efficient delivery of antigen to DCs using yeast-derived microparticles
Ying Pan1, Xiaopeng Li1, Tianyi Kang1
1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, P. R. China.
Scientific Reports
|May 30, 2015
Summary
Yeast shell microparticles offer a safe alternative for cancer vaccine delivery. These microparticles enhance antigen uptake by immune cells, promoting a robust anti-tumor response for effective cancer immunotherapy.
Area of Science:
- Biotechnology
- Immunology
- Materials Science
Background:
- Antigen-presenting cells (APCs) naturally internalize pathogens for vaccine delivery.
- Live pathogen vaccines face biosafety concerns, limiting clinical use.
- Developing safe and effective vaccine delivery systems is crucial for cancer immunotherapy.
Purpose of the Study:
- To develop and evaluate yeast shell (YS) microparticles as a novel vaccine delivery system for cancer immunotherapy.
- To investigate the potential of YS microparticles in enhancing antigen presentation and triggering anti-tumor immune responses.
Main Methods:
- Bread yeast was chemically treated to create capsular yeast shell (YS) microparticles (~3.4 μm).
- Ovalbumin (OVA) was conjugated to the YS microparticle surface as a model antigen.
- Interaction of YS-OVA microparticles with dendritic cells (DCs) was assessed, including cellular uptake and DC maturation markers.
- In vivo immunization studies were conducted to evaluate the anti-tumor immune response.
Main Results:
- YS microparticles were successfully prepared and shown to be recognized and internalized by dendritic cells (DCs).
- YS-mediated antigen delivery enhanced antigen uptake by DCs, promoted DC maturation, and stimulated the release of immune co-stimulatory molecules.
- Immunization with YS-mediated antigen induced significant humoral and cellular immune responses against tumor cells in vivo.
Conclusions:
- Yeast shell microparticles serve as an efficient and safe platform for vaccine delivery.
- YS microparticles show promise for enhancing anti-tumor immunity in cancer immunotherapy.
- This approach offers a viable alternative to live pathogen-based vaccines.
